Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Myeloid 2Gynecologic 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 283Cisplatin 225Pemetrexed 196Paclitaxel 151Docetaxel 132pembrolizumab 109Gemcitabine 94Etoposide 64Erlotinib Hydrochloride 59Radiotherapy 54Vinorelbine 47durvalumab 46Gefitinib 46Bevacizumab 46atezolizumab 42Nivolumab 40Drug Therapy 34osimertinib 30Topotecan 29tislelizumab 23130-nm albumin-bound paclitaxel 23Radiosurgery 21Ipilimumab 18Crizotinib 18Magnetic Resonance Spectroscopy 15Albumin-Bound Paclitaxel 15Surgical Procedures, Operative 14aumolertinib 13Platinum 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × BID protein, human × Thoracic × Clear all
NCT04624204 2026-05-26

MK 7339-013

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
672 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06082635 2025-05-18

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Shenzhen TargetRx Co., Ltd.

Phase 3 Active not recruiting
321 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡